MIMEDX Expands Surgical Portfolio with New Product Launch
Published: 18 Mar 2026
Author: Precedence Research
MiMedx Group, Inc. has announced the commercial launch of AMNIOFIX Thyroid Shields, expanding its surgical product portfolio and strengthening its presence in regenerative biomaterials used in healthcare procedures. The new product represents an extension of the company’s existing AMNIOFIX line of dehydrated human amniotic/chorionic membrane (DHACM) allografts.
The launch highlights the company’s continued focus on developing innovative products designed to support healing and improve surgical outcomes. By introducing a specialised solution for endocrine surgery, MIMEDX aims to address specific challenges faced during thyroid and parathyroid procedures while expanding the clinical applications of its AMNIOFIX technology.
According to Towards Healthcare, the Endotracheal Tube Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.34 billion in 2026 to approximately USD 4.24 billion by 2035, representing a compound annual growth rate (CAGR) of 6.84% from 2026 to 2035. This market expansion is largely driven by the rising prevalence of respiratory diseases, increasing surgical procedures, and growing demand for advanced airway management in emergency and critical care settings.
Designed for Endocrine Surgery Procedures
AMNIOFIX Thyroid Shields are specifically designed for use in endocrine surgeries, particularly following thyroidectomy procedures. During these operations, surgeons often expose critical structures such as the recurrent laryngeal nerve and the parathyroid glands. The newly launched shields are applied directly to these areas to act as a protective barrier and help support the body’s natural healing process.
The sheets are provided in preconfigured sizes, allowing surgeons to use them without the need for modifications during the operation. This feature is intended to simplify the surgical workflow and potentially save valuable time in the operating room. Additionally, the product is manufactured using the company’s proprietary PURION processing technology and can remain shelf-stable for up to five years, offering convenience for healthcare providers.
Addressing Risks Associated with Thyroid Surgery
One of the major concerns during thyroid and parathyroid surgeries is the potential for injury to the recurrent laryngeal nerve. Damage to this nerve can lead to complications affecting voice production and may increase the risk of aspiration. According to company officials, the new product configuration is designed to help mitigate these risks by protecting the exposed nerve during surgery.
Clinical findings cited by the company further support the product’s potential benefits. A retrospective single-centre study compared patients who received the AMNIOFIX application with those who did not. Results indicated a 76% reduction in recurrent laryngeal nerve damage within 24 hours after surgery among patients treated with the protective barrier.
Strengthening MIMEDX’s Regenerative Medicine Strategy
The introduction of AMNIOFIX Thyroid Shields aligns with MIMEDX’s broader strategy of expanding its portfolio of regenerative biomaterial products. The company focuses on solutions designed to support tissue repair and healing across wound care, burn treatment, and surgical applications.
With more than a decade of experience in regenerative medicine technologies, MIMEDX continues to invest in product innovation aimed at improving patient outcomes and advancing surgical care. The latest launch demonstrates the company’s commitment to expanding clinical use cases for its placental-derived biomaterial technologies while reinforcing its position in the global healthcare market.
A recent report by Towards Healthcare highlights that the Endotracheal Tube Market is experiencing steady development as healthcare providers increasingly adopt advanced airway management devices to improve patient safety and ventilation efficiency. Endotracheal tubes are widely used in operating rooms, intensive care units, and emergency departments for mechanical ventilation, anaesthesia delivery, and airway protection during critical medical procedures and life-support interventions.